Home » Health » Moderna Vaccine is Claimed to be 100% Effective in Preventing Coronavirus Severe Pain

Moderna Vaccine is Claimed to be 100% Effective in Preventing Coronavirus Severe Pain

Jakarta, CNBC Indonesia – The pharmaceutical company Moderna officially submitted an application to the United States Food and Drug Administration (FDA) for a permit to use the Covid-19 emergency which it developed on Monday (30/11/2020).

Moderna asked the FDA to review an expanded set of clinical trial data that showed its vaccine was 94.1% effective at preventing Covid-19 and 100% effective at preventing severe cases of the disease.

“This is shocking,” said Dr. Paul Offit, a member of the FDA’s vaccine advisory committee, was quoted as saying by CNN International, Tuesday (12/1/2020). “This is incredible data.”


Even Moderna’s Chief Medical Officer Dr Tal Zaks said he became emotional when he saw the clinical trial data on Saturday night (29/11/2020).

“It was the first time I allowed myself to cry,” said Dr. Tal Zaks. “We have full hopes of changing the course of this pandemic.”

Moderna is the second company to apply for an emergency use permit with the FDA. On November 20, Pfizer submitted data showing high efficacy.

The FDA will meet with its advisory committee this December to review applications from Pfizer and Moderna. Moderna also plans to apply for a permit with European health authorities for an emergency use permit.

Moderna began conducting final stage clinical trials of the Covid-19 vaccine in July 2020 on 30,000 volunteers in the United States. In this trial 195 people fell ill. 30 people became seriously ill and one died, but none of them were given the Moderna vaccine.

The trial included a large number of people in the groups most at risk, with 7,000 people over 65 and more than 5,000 young people with chronic diseases, such as diabetes, severe obesity and heart disease.

The study involved 11,000 people from black, Asian and minority ethnic communities, said Moderna, who made up 37%, the same proportion as the US population. Even so, complete data has not been released.

By the end of 2020, Moderna expects about 20 million doses of its vaccine to be available in the United States, and will produce 500 million to 1 billion doses globally next year, according to the company’s press release on Monday.

(roy/miq)


– .

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.